Nurix Therapeutics (NASDAQ:NRIX) Now Covered by Analysts at Leerink Partners

Analysts at Leerink Partners initiated coverage on shares of Nurix Therapeutics (NASDAQ:NRIX) in a research report issued on Monday,Briefing.com Automated Import reports. The firm set a “market perform” rating and a $16.00 price target on the stock. Leerink Partners’ price target suggests a potential upside of 17.73% from the company’s current price.

Several other research analysts have also recently weighed in on NRIX. HC Wainwright upped their price objective on Nurix Therapeutics from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. BMO Capital Markets initiated coverage on shares of Nurix Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $35.00 price target for the company. Stifel Nicolaus raised their target price on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Royal Bank of Canada boosted their price target on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. Finally, JPMorgan Chase & Co. lowered their target price on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $30.88.

Nurix Therapeutics Price Performance

NASDAQ:NRIX opened at $13.59 on Monday. The business’s 50-day simple moving average is $17.54 and its 200-day simple moving average is $21.14. Nurix Therapeutics has a fifty-two week low of $11.90 and a fifty-two week high of $29.56. The stock has a market capitalization of $1.03 billion, a PE ratio of -4.70 and a beta of 2.18.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. On average, research analysts expect that Nurix Therapeutics will post -2.99 earnings per share for the current year.

Insider Buying and Selling

In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,811 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35. Following the transaction, the chief financial officer now owns 39,549 shares in the company, valued at $785,047.65. This represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the sale, the insider now owns 55,937 shares of the company’s stock, valued at approximately $1,110,349.45. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 12,326 shares of company stock valued at $213,449. Company insiders own 7.20% of the company’s stock.

Institutional Trading of Nurix Therapeutics

A number of institutional investors have recently modified their holdings of the stock. US Bancorp DE increased its holdings in Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after buying an additional 842 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Nurix Therapeutics in the 4th quarter valued at $28,000. Amalgamated Bank raised its holdings in shares of Nurix Therapeutics by 30.6% during the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock worth $49,000 after buying an additional 511 shares in the last quarter. Quarry LP lifted its position in shares of Nurix Therapeutics by 3,746.2% during the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after buying an additional 2,435 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in Nurix Therapeutics in the fourth quarter valued at about $87,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.